HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combined heart and liver transplantation can be safely performed with excellent short- and long-term results.

AbstractBACKGROUND:
Heart transplant has become the gold standard therapy for end-stage heart failure. Short- and long-term outcomes after orthotopic heart transplant have been excellent. Many patients with heart failure manifest hepatic failure as a result of a chronically elevated central venous pressure. Concomitant hepatic failure has been a contraindication to heart transplant in most centers. A few select institutions are currently performing combined heart-liver transplantation to treat dual organ failure. The outcomes after dual organ transplant are largely unknown, with limited data from a few select centers. We undertook this study to analyze our large experience with combined heart-liver transplant and determine the short-term and long-term outcomes associated with this procedure.
METHODS:
We have performed 1,050 heart transplants at our center to date. Of these patients, 26 underwent combined heart and liver transplant (largest single-center experience). We reviewed demographic, perioperative, and short- and long-term outcomes after this combined procedure.
RESULTS:
All 26 patients underwent successful dual organ transplant, without any episodes of primary graft dysfunction. Average length of intensive care unit stay was 10 ± 5 days, and average hospital stay was 25 ± 11 days. Kaplan-Meier analysis demonstrated excellent short-term survival (1 year, 87% ± 7%) and long-term survival (5 years, 83% ± 8%). Interestingly, only 3 patients (11%) demonstrated any evidence of rejection long-term by myocardial biopsy, suggesting that concomitant hepatic transplantation may provide immunologic protection for the cardiac allograft.
CONCLUSIONS:
We present the largest single-center series of combined heart and liver transplant. This dual organ strategy is highly feasible, with excellent long-term survival. Concomitant liver transplant may confer immunologic protection for the cardiac allograft.
AuthorsPavan Atluri, Ann Gaffey, Jessica Howard, Emily Phillips, Andrew B Goldstone, Nicole Hornsby, John W MacArthur, Jeffrey E Cohen, Jacob Gutsche, Y Joseph Woo
JournalThe Annals of thoracic surgery (Ann Thorac Surg) Vol. 98 Issue 3 Pg. 858-62 (Sep 2014) ISSN: 1552-6259 [Electronic] Netherlands
PMID25069688 (Publication Type: Journal Article)
CopyrightCopyright © 2014 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
Topics
  • Female
  • Heart Failure (complications, surgery)
  • Heart Transplantation (methods)
  • Humans
  • Liver Failure (complications, surgery)
  • Liver Transplantation (methods)
  • Male
  • Middle Aged
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: